IRIS
MINOTTI, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.331
NA - Nord America 1.467
EU - Europa 770
SA - Sud America 35
OC - Oceania 33
AF - Africa 18
Totale 9.654
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 5.467
US - Stati Uniti d'America 1.403
HK - Hong Kong 885
CN - Cina 834
GB - Regno Unito 238
DE - Germania 134
IT - Italia 82
CZ - Repubblica Ceca 72
IN - India 54
NL - Olanda 53
CA - Canada 46
FI - Finlandia 33
AU - Australia 32
RU - Federazione Russa 31
JP - Giappone 25
BR - Brasile 22
BE - Belgio 21
UA - Ucraina 17
MX - Messico 16
TR - Turchia 16
PL - Polonia 14
ZA - Sudafrica 14
FR - Francia 12
ES - Italia 11
ID - Indonesia 9
SE - Svezia 9
EE - Estonia 8
LT - Lituania 6
TW - Taiwan 6
AE - Emirati Arabi Uniti 5
AR - Argentina 5
IQ - Iraq 5
CL - Cile 4
HU - Ungheria 4
RO - Romania 4
AT - Austria 3
MY - Malesia 3
PT - Portogallo 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BD - Bangladesh 2
BY - Bielorussia 2
EC - Ecuador 2
GE - Georgia 2
HR - Croazia 2
IE - Irlanda 2
IL - Israele 2
IR - Iran 2
KZ - Kazakistan 2
NA - Namibia 2
PK - Pakistan 2
SI - Slovenia 2
AM - Armenia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CH - Svizzera 1
CO - Colombia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EG - Egitto 1
JO - Giordania 1
KR - Corea 1
KW - Kuwait 1
LK - Sri Lanka 1
MA - Marocco 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
RS - Serbia 1
SA - Arabia Saudita 1
TH - Thailandia 1
YE - Yemen 1
Totale 9.654
Salva come PNG Salva come JPEG
Città #
Hong Kong 877
Hefei 454
Singapore 448
Ashburn 327
Boardman 268
London 204
Shanghai 145
Beijing 114
Munich 71
Council Bluffs 64
Los Angeles 61
San Francisco 58
Redmond 56
Brno 54
Dallas 51
Amsterdam 41
Pune 34
Rome 33
Santa Clara 33
Toronto 28
Washington 22
New York 21
Seattle 19
Turku 19
Brooklyn 18
Melbourne 17
Olomouc 17
Hasselt 16
West Jordan 16
Mexico City 15
São Paulo 15
Helsinki 14
Tokyo 14
Chicago 13
Warsaw 12
Boston 11
Canberra 10
Guangzhou 10
Manchester 9
Phoenix 9
Chennai 8
Johannesburg 8
Atlanta 7
Haikou 6
Ankara 5
Hanover 5
New Delhi 5
Oklahoma City 5
Paris 5
Stockholm 5
Sydney 5
Bengaluru 4
Catania 4
Charlotte 4
Hangzhou 4
Montreal 4
Moscow 4
Shenzhen 4
St Petersburg 4
Sulaymaniyah 4
Tenri 4
The Dalles 4
Almere Stad 3
Budapest 3
Central 3
Dunstable 3
Genoa 3
Ivanovo 3
Mol 3
Nizhniy Novgorod 3
North Liberty 3
Petaling Jaya 3
Poplar 3
Secaucus 3
Sona 3
Taipei 3
Tallinn 3
Tianjin 3
Vilnius 3
Wuhan 3
Alba 2
Augusta 2
Aversa 2
Berlin 2
Buenos Aires 2
Buffalo 2
Cincinnati 2
Cleveland 2
Concord 2
Denver 2
Dublin 2
Fremont 2
Gatchina 2
Hoellviken 2
Innsbruck 2
Iowa City 2
Ljubljana 2
Lodz 2
Luoyang 2
Milan 2
Totale 3.920
Salva come PNG Salva come JPEG
Nome #
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 195
Proceedings of an International Workshop on Anthracycline Cardiotoxicity 187
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 182
Cancer drugs and QT prolongation: weighing risk against benefit 182
Cell Biology and Toxicology: Special Issue on Cardiovascular Liability of Drugs 182
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 182
An investigation into thee mechanism of citrateFE2+-dependent lipid peroxidation 180
A supposed role for superoxide dismutase in the control of tumor growth 174
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 173
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 170
Minimal sampling colistin pharmacokinetics in critically ill patients 170
A Special Section on Clinical Pharmacology-Editorial 169
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 168
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 168
Cardio-oncology in clinical studies and real life 166
Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study. 165
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 161
Acute Heart Failure 29 Years After Treatment for Childhood Cancer 160
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 157
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 155
Adriamycin dependent release of iron from human lung tumor microsomes : Biochemical mechanisms and clinical implications 154
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 152
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 135
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines 117
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 114
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 104
Anthracyclines 103
Anthracycline Cardiotoxicity 100
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 98
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 97
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 94
Anthracycline Cardiotoxicity 87
Activation of heme oxygenase and consequent carbon monoxide formation inhibits the release of arginine vasopressin from rat hypothalamic explants. Molecular linkage between heme catabolism and neuroendocrine function. Mol Brain Res. 84
Anthracycline cardiotoxicity 84
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 83
Anthracycline metabolism and toxicity in human myocardium : Comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with reduced formation and [4Fe-4S]-reactivity of its secondary alcohol metabolite 82
An Invitation from the Editors of Cardio-Oncology 80
Adriamycin dependent release of iron from microsomal membranes 79
All Eyes on Me, Please: Ocular Palonosetron for the Cancer Patient with Nausea and Vomiting 76
An introduction to the metabolic determinants of anthracycline cardiotoxicity 76
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). 76
Adriamycin alcohol dependent iron mobilization : A novel mechanism of adriamycin cardiotoxicity? 75
Cardiotoxicity of antitumor drugs 70
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 67
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 66
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 60
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 44
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 44
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement 43
What is cardiotoxicity? 42
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 36
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 36
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 35
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 35
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 34
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 33
Isavuconazole: case report and pharmacokinetic considerations 33
Pharmacology of Cardio-Oncology 33
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 33
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 32
Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis 32
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology 32
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 32
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 31
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 30
Pixantrone: novel mode of action and clinical readouts. 30
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 30
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. 29
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 29
The concomitant management of cancer therapy and cardiac therapy 29
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 29
Drug-induced hepatotoxicity in cancer patients - implication for treatment 29
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 27
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 27
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 27
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma 27
Cardiac imaging in childhood cancer survivors: a state-of-the-art review 26
Redox cycling of iron and lipid peroxidation 26
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 26
Quantitative evaluation of the activity of the malate-aspartate shuttle in Ehrlich ascites tumor cells. 25
Pharmacological Foundation of Cardio-Oncology 25
Matters of the heart: The case of TNF-alpha targeting drugs 25
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 25
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 25
Cardiotoxicity of antitumor drugs 25
Role of iron in anthracycline cardiotoxicity : New tunes for an old song ? 25
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 25
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. 25
null 24
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. 24
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 24
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin 24
Doxorubicin degradation in cardiomyocytes 23
The role of iron in the initiation of lipid peroxidation. 23
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 23
Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis. 23
Human heart cytosolic reductases and anthracycline cardiotoxicity. 23
gamma-Glutamyltransferase-dependent prooxidant reactions: A factor in multiple processes. 23
Factors influencing superoxide and t-BuOOH dependent lipid peroxidation of tumor microsomes 23
Lipid peroxidation of microsomes from Morris hepatoma 3924A : order parameter and dynamic properties determined by fluorescence anisotropy decay 23
Totale 7.425
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.773
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.773
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022527 0 5 0 1 0 1 2 214 7 7 7 283
2022/2023108 2 4 5 8 7 5 13 0 2 7 51 4
2023/2024776 22 87 29 55 96 329 9 29 6 24 10 80
2024/20257.426 150 67 268 29 72 168 91 32 690 586 2.541 2.732
2025/2026995 714 281 0 0 0 0 0 0 0 0 0 0
Totale 9.832